Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Clinical trials participation is directly influenced by the information received...
Dr Daniel Vorobiof - Belong.Life, New York, USA
Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )
4 Jun 2021
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resect...
Dr Jonathan Spicer - McGill University, Montreal, Canada
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )
4 Jun 2021
Incidence and trends of HPV-related cancers in the United States
Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francis...
Incidence and trends of HPV-related cancers in the United States ( Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
4 Jun 2021
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Dr Neal Shore and Prof Oliver Sartor
ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )
4 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advan...
Dr Ian Chau - The Royal Marsden, London, UK
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau -  The Royal Marsden, London, UK )
4 Jun 2021
ASCO 2021: Renal cancer roundup
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021
Olaparib improves disease-free survival in high-risk early-stage HER2-negative b...
Prof Andrew Tutt - Institute of Cancer Research, London, UK
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )
4 Jun 2021
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy f...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021
European Cancer Organisation - Time to Act
Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands
European Cancer Organisation - Time to Act ( Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands )
19 May 2021